Roche Holding's non-GAAP EPS was 10.23 Swiss francs, sales were 29.85 billion Swiss francs, and the outlook for fiscal year 24 was revised upward

Roche Holding press release (OTCQX: RHHBY): Non-GAAP EPS for the first half of the year was 10.23 Swiss francs.

Net sales of 29.85 billion Swiss francs (up 0.2% from the same period last year).

Core operating profit increased 11% on a CER basis.

Sales in the pharmaceutical sector were 22.6 billion Swiss francs (2023:22.5 billion Swiss francs), up 5% on a CER basis.

Sales in the diagnostic medicine division were 7.2 billion Swiss francs (2023:7.3 billion Swiss francs), an increase of 5% on a CER basis.

Operating free cash flow was 8.1 billion Swiss francs, an increase of 9% on a CER basis (stable on a Swiss franc basis).

2024 guidance raised Group sales growth in the middle of the single-digit range, core EPS growth in the latter half of the single-digit range: further increase in Swiss franc-denominated dividends.